Chad Phipps Sells 3,000 Shares of Zimmer Biomet (NYSE:ZBH) Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Zimmer Biomet Price Performance

ZBH stock opened at $92.30 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $106.88. The stock has a market cap of $17.61 billion, a PE ratio of 22.46, a P/E/G ratio of 1.79 and a beta of 0.47. The firm has a 50 day simple moving average of $95.42 and a two-hundred day simple moving average of $91.51.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter last year, the company posted $2.07 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ZBH. Royal Bank Of Canada boosted their target price on Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. UBS Group reissued a “buy” rating and set a $120.00 price target on shares of Zimmer Biomet in a research note on Thursday, August 6th. Stifel Nicolaus upped their price objective on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. BMO Capital Markets reaffirmed a “market perform” rating and set a $96.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Finally, Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $104.42.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Core Capital Management & Research inc. purchased a new stake in Zimmer Biomet in the 2nd quarter worth approximately $101,000. National Pension Service increased its stake in shares of Zimmer Biomet by 3.2% during the second quarter. National Pension Service now owns 199,437 shares of the medical equipment provider’s stock valued at $17,170,000 after buying an additional 6,199 shares during the period. Engineers Gate Manager LP bought a new position in shares of Zimmer Biomet during the second quarter valued at approximately $6,162,000. Integrated Wealth Concepts LLC purchased a new stake in Zimmer Biomet in the second quarter worth $137,000. Finally, NewEdge Advisors LLC lifted its stake in Zimmer Biomet by 34.5% in the second quarter. NewEdge Advisors LLC now owns 4,779 shares of the medical equipment provider’s stock worth $411,000 after acquiring an additional 1,226 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.